New developments in IL-6 dependent biology and therapy: Where do we stand and what are the options?

Expert Opinion on Investigational Drugs

Volumn 8, Issue 9, 1999, Pages 1327-1349

  Kallen, K J ^a   Galle, P R ^a   Rose John, S ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

AIDS; Antagonist; Apoptosis; Castleman's disease; Cytokine; Haematopoiesis; Interleukin 6; Ischaemia; Liver regeneration; Lupus; Multiple myeloma; Myocardial infarction; Nephritis; Osteoporosis; Paget's disease; POEMS syndrome; Prostate carcinoma; Receptor; Rheumatoid arthritis; Vasculitis

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 ANTAGONIST; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN; RECEPTOR SUBUNIT; RECOMBINANT ANTIBODY; RECOMBINANT INTERLEUKIN 6; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BONE MARROW CELL; CLINICAL TRIAL; DRUG RESEARCH; ENTERITIS; GLOMERULONEPHRITIS; HEART INFARCTION; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LIVER REGENERATION; MULTIPLE MYELOMA; NONHUMAN; OSTEOPOROSIS; PAGET BONE DISEASE; PARAPROTEINEMIA; PROSTATE CARCINOMA; RECEPTOR BINDING; REVIEW; RHEUMATIC DISEASE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPOIESIS; UNSTABLE ANGINA PECTORIS; VIRUS INFECTION;

EID: 0032817930     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.8.9.1327     Document Type: Review

References (254)